More information: One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice, JAMA Network Open (2024). DOI: 10.1001/jamanetworkopen.2024.33326. Provided by Cleveland Clinic.

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

In a randomized trial of 2.4-mg semaglutide, 3.0-mg liraglutide, and matching placebo for both, those on semaglutide plus diet and exercise saw a 9.4% greater average loss in baseline weight ...

That mark was reached by 28.6% of those taking liraglutide for obesity, 23.1% of semaglutide diabetics and 12.3% of liraglutide diabetics.

This retrospective cohort study included 3,389 adult patients with obesity who initiated treatment with injectable semaglutide or liraglutide between July 1, 2015, and June 30, 2022.

A new study published by Cleveland Clinic researchers in Diabetes, Obesity and Metabolism investigating the genetic ...

The researchers found that the mean percentage weight change at one year was –5.1% and –2.2% with semaglutide and liraglutide, respectively; –3.2% and –5.9% for T2D and obesity as ...

One-year weight reduction with semaglutide or liraglutide in clinical practice. JAMA Network. Journal JAMA Network Open. Keywords /Life sciences/Organismal biology/Morphology/Body weight/ Weight loss ...

Semaglutide was the clear weight-loss winner compared with liraglutide, from the same drug class, when added to lifestyle counseling for people with overweight/obesity but not diabetes, a study shows.

A new study finds a significant link between the use of semaglutide drugs such as Ozempic, which are often used for weight loss, antidepressant, or benzodiazepine use, and suicidal ideation.

Semaglutide and liraglutide were associated with risk for somatic hospitalization. Patients with alcohol use disorder who used GLP-1 agonists to treat obesity or type 2 diabetes had a decreased ...

The researchers found that the mean percentage weight change at one year was –5.1% and –2.2% with semaglutide and liraglutide, respectively; –3.2% and –5.9% for T2D and obesity as ...